Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
US FDA Performance Tracker Drug Review Drug Approval Standards

Keeping Track: US FDA Receives Advanced Biologic BLAs From ImmunityBio, CSL; Nymox, Medac Stumble

  • News

Executive Summary

The latest NDA and BLA submission news and highlights from the Pink Sheet’s US FDA Performance Tracker

You may also be interested in...



Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track: US FDA Approves Carvykti, Vonjo, But Turns Down Lenacapavir, Filsuvez And GC1507

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.

Table

View full table

Related Content

Scrip
Pink Sheet

Topics

Related Companies

Tags:
US FDA Performance Tracker Drug Review Drug Approval Standards
Latest News

COVID-19 Vaccine Refresh For Boosters Only? US FDA Position On Primary Series May Have Shifted

PDUFA Collections Exceeded Target In FY 2021, While GDUFA Fell Short

Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too

US FDA’s Science Strategies Program Aims To Proactively Tackle Drug Development Hurdles

UsernamePublicRestriction

Register

PS146267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By